Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

416
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
416
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

593
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
593
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Angina IV: Management01:26

Angina IV: Management

359
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
359
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

580
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ALIGNED Network for rare cerebrovascular diseases: methodology and preliminary results.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Experimental Approach to Moyamoya Angiopathy: Insights into Vascular Cell Crosstalk.

Cells·2026
Same author

Sex-based differences in emergency department treatment times for acute ischaemic stroke: evidence from a large Italian cohort.

European stroke journal·2026
Same author

Amyloid PET Burden, CSF Biomarkers, and <i>APOE</i> Genotype in People With Iatrogenic and Sporadic Cerebral Amyloid Angiopathy.

Neurology·2026
Same author

Neurological management and outcome measures in Fabry disease: consensus statements from the Italian Fabry disease neurological working group.

Orphanet journal of rare diseases·2026
Same author

From cognition to daily functioning: Insights from iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Related Experiment Video

Updated: Feb 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

CADASIL: Treatment and Management Options.

Anna Bersano1, Gloria Bedini2, Joshua Oskam3

  • 1Cerebrovascular Unit, Carlo Besta Neurological Institute IRCCS Foundation, Via Celoria 23, 20133, Milan, Italy. anna.bersano@gmail.com.

Current Treatment Options in Neurology
|July 26, 2017
PubMed
Summary

Cerebral Autosomal-Dominant Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CADASIL) is a severe neurological disease lacking disease-modifying therapies. Further research and clinical trials are crucial for developing effective treatments to halt CADASIL progression.

Keywords:
CADASILNOTCH3 genePathogenesisTherapy

Related Experiment Videos

Last Updated: Feb 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.2K

Area of Science:

  • Neurology
  • Genetics
  • Vascular Biology

Background:

  • Cerebral Autosomal-Dominant Arteriopathy with Subcortical infarcts and Leukoencephalopathy (CADASIL) is a severe, inherited cerebrovascular disorder.
  • Current management focuses on symptomatic relief, with no approved therapies to slow disease progression.

Purpose of the Study:

  • To review the current understanding of CADASIL.
  • To highlight the urgent need for evidence-based therapeutic strategies.

Main Methods:

  • Review of existing literature on CADASIL.
  • Analysis of current treatment approaches and research gaps.

Main Results:

  • No therapies currently exist that can limit the progression of CADASIL.
  • Emerging findings require confirmation through further in vivo studies and multi-center trials.

Conclusions:

  • There is a critical need for robust clinical trials to identify effective therapies for CADASIL.
  • Developing evidence-based treatments is essential to improve outcomes for patients with this disabling disease.